| Background: Immune-therapy induced by cytokine is a popular method in recent years. However, cytokine usually has dual immune roles: on the one hand, it can improve the anti-tumor immunologic reaction; on the other hand, it can also play a role in the process of the occurrence and progress of tumors. It is known that some kinds of tumor cell and tumor cell line can produce cytokines, such as renal cell carcinoma and Kaposi's fleshy tumor secreting tumor necrosis factor (TNF). The cytokines may promote the growth and metastasis of these tumors. Interferon gamma (IFN-y) is one of the cytokines, which is used earlier and popularly. It can serve as anti-tumor in many ways. It has been previously presumed to be produced by activated T and NK lymphoid cells, mononuclear cells, macrophage and dendritic cells. Our previous studies showed that some material like iFN-y was expressed in 47% (8/17) adrenal adenoma, 100% (7/7) adenocarcinoma, 93.7% (15/16) pheochromocytoma by immunohistochemistry. The antibody used was a monoclonal antibody against rat IFN-γ not human IFN-γ, so it could not be inferred that it was hlFN-γ. The questions are raised by these observations: 1) What is the immunoreactivity really? 2) Wheater is it produced by tumor cell itself? 3) What is the relationship between the tumor and the IFN-y? 4) If the IFN-y might be detected out in othertumor tissues, what is the rule of it? In this way it is important to study the expression of IFN-y in tumor tissues and the rule of it. Moreover, it has considerable significance for detecting the relationship between the IFN-γ and the tumor.Objectives: To detect the expression of IFN-y in different tumor tissues including adrenal adenoma, adenocarcinoma, pheochromocytoma, and renal cell carcinoma. To analyze the relationship between expression of IFN-γ and histological differentiation of tumors and to investigate the significance of IFN-y in the process of pathogenesis and progress of tumors.Methods: (1) Immunohistochemistry was used to detect the expression of IFN-y in 35 cases of adrenal cortical adenoma, 4 cases of adrenal cortical adenocarcinoma, 30 cases of pheochromocytoma, 9 cases of adrenal gland tissue around carcinoma, 60 cases of renal cell carcinoma, 23 cases of kidney tissues around renal cell carcinoma, 5 cases of kidney tissue which have nothing about tumor of kidney, 20 cases of hepatocarcinoma, 10 cases of breast cancer, 10 cases of gastric cancer, 10 cases of colon carcinoma, 10 cases of pulmonary carcinoma, 10 cases of thyroid carcinoma, 10 cases of carcinoma of larynx, 10 cases of pancreatic carcinoma, 10 cases of carcinoma of bladder, 10 cases of skin squamous carcinoma, 10 cases of cancer of the cervix, 10 cases of nasopharyngeal carcinoma, 10 cases of lymphoma, 10 cases of axtrocytoma, 10 cases of meningioma, 10 cases of rhabdomyosarcoma, 10 cases of fibrosarcoma, 10 cases of osteosarcoma, 10 cases of hemangioma, 10 cases of adenoma, 10 cases of fibroadenoma, 10 casesof teratoma, 10 cases of leiomyoma, 10 cases of pituitary adenoma, 10 cases of thyroid tumor and 10 cases of cutaneous papilloma. (2) In situ hybridization was used to exam the expression of IFN-γ mRNA in tissues of adrenal adenoma, adenocarcinoma, pheochromocytoma, adrenal gland tissues around neoplasia and renal cell carcinoma to study the distribution of IFN-γmRNA. (3) The Western blot was used to detect the expression of IFN-y in 6 cases of fresh adrenal 1 adenoma, 5 cases of adrenal pheochromocytoma and 14 cases of renal cell carcinoma. (4) The relationship between expression of IFN-y and histological differentiation of tumors was analyzed with statistical methods.Results: (1) The results of immunohistochemistry showed that IFN-γ was expressed in 34.3% (12/35) adrenal adenoma, 50% (2/4) adenocarcinoma, 26.7% (8/30) pheochromocytoma, 22.2% (2/9) adrenal cortex tissues around tumors and 40% (2/5) adrenal medulla tissues around tumors. IFN-y was expressed in 26.7% (16/60) renal cell carcinoma, and it was not expressed in 23 cases of tissues around renal cell carcinoma and 5 cases of normal kidney tissues. IFN-y was not expressed in 20 cases of hepaloceilular and.10 cases of breast cancer, gastric carcinoma and pulmonary carcinoma tissues. (2) The results of in situ hybridization showed that IFN-y mRNA was expressed in 37.1% (13/35) adrenal adenoma, 50% (2/4) adenocarcinoma, 30% (9/30) pheochromocytoma, 22.2% (2/9) adrenal cortical tissues around tumors and 40% (2/5) adrenal medulla tissues. 26.7% (16/60) renal cell carcinoma tissues expressed IFN-y mRNA, but kidney tissues around carcinoma and 5 cases of normal kidney did not expressed IFN-y mRNA. IFN-y mRNA was not expressed in hepatocellular carcinoma, breast... |
PDF Full Text Request